Neurocrine Biosciences, Inc. (FRA:NB3)

Market Cap	11.26B +32.3%
Revenue (ttm)	2.44B +21.4%
Net Income	407.62M +40.2%
EPS	3.98 +41.9%
Shares Out	n/a
PE Ratio	27.62
Forward PE	13.21
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	8
Open	110.75
Previous Close	110.25
Day's Range	110.75 - 112.70
52-Week Range	86.98 - 137.70
Beta	n/a
RSI	53.61
Earnings Date	May 5, 2026

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical develo...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1992
• Employees: 2,000
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NB3

Financial Performance

In 2025, Neurocrine Biosciences's revenue was $2.86 billion, an increase of 21.45% compared to the previous year's $2.36 billion. Earnings were $478.60 million, an increase of 40.23%.

Financial numbers in USD